4.7 Article

Enhancement of radiotherapy efficacy by miR-200c-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer cells

期刊

INTERNATIONAL JOURNAL OF NANOMEDICINE
卷 9, 期 -, 页码 2345-2358

出版社

DOVE MEDICAL PRESS LTD
DOI: 10.2147/IJN.S60874

关键词

radiosensitizer; miR-200c; gelatinase-stimuli nanoparticles; cancer stem cell-like properties; gastric cancer

资金

  1. National Natural Science Foundation of China [81071815, 81172281, 81220108023, 81101751, 81101816, 81302053]
  2. Jiangsu Provincial Special Program of Medical Science [BL2012001]
  3. Nanjing Medical Science and Technique Development Foundation
  4. Nanjing Medical Science and Technique Development Foundation [JQX12003]

向作者/读者索取更多资源

Radiotherapy is the main locoregional control modality for many types of unresectable tumors, including gastric cancer. However, many patients fail radiotherapy due to intrinsic radioresistance of cancer cells, which has been found to be strongly associated with cancer stem cell (CSC)-like properties. In this study, we developed a nanoparticle formulation to deliver miR-200c, which is reported to inhibit CSC-like properties, and then evaluated its potential activity as a radiosensitizer. miR-200c nanoparticles significantly augmented radiosensitivity in three gastric cancer cell lines (sensitization enhancement ratio 1.13-1.25), but only slightly in GES-1 cells (1.06). In addition to radioenhancement, miR-200c nanoparticles reduced the expression of CD44, a putative CSC marker, and the percentage of CD44(+) BGC823 cells. Meanwhile, other CSC-like properties, including invasiveness and resistance to apoptosis, could be suppressed by miR-200c nanoparticles. CSC-associated radioresistance mechanisms, involving reactive oxygen species levels and DNA repair capacity, were also attenuated. We have demonstrated that miR-200c nanoparticles are an effective radiosensitizer in gastric cancer cells and induce little radiosensitization in normal cells, which suggests that they are as a promising candidate for further preclinical and clinical evaluation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据